Sei Investments Co. Boosts Holdings in Apyx Medical Corporation $APYX

Sei Investments Co. grew its position in shares of Apyx Medical Corporation (NASDAQ:APYX) by 298.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 598,255 shares of the company’s stock after purchasing an additional 448,174 shares during the period. Sei Investments Co.’s holdings in Apyx Medical were worth $2,208,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nantahala Capital Management LLC raised its position in shares of Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after buying an additional 80,000 shares in the last quarter. Osaic Holdings Inc. bought a new position in Apyx Medical in the 2nd quarter worth about $50,000. Vanguard Group Inc. raised its holdings in shares of Apyx Medical by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after acquiring an additional 53,175 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Apyx Medical in the 3rd quarter valued at about $59,000. Finally, Citadel Advisors LLC bought a new stake in shares of Apyx Medical during the 3rd quarter valued at about $28,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Trading Down 2.6%

Shares of APYX opened at $4.05 on Friday. Apyx Medical Corporation has a fifty-two week low of $1.70 and a fifty-two week high of $5.08. The firm has a market cap of $169.74 million, a price-to-earnings ratio of -20.25 and a beta of 1.39. The firm has a 50 day moving average price of $4.24 and a 200-day moving average price of $3.94. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.18%. As a group, equities research analysts forecast that Apyx Medical Corporation will post -0.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

APYX has been the topic of a number of recent analyst reports. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. HC Wainwright started coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.